AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeidner, N. S.
Right arrow Articles by Piesman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeidner, N. S.
Right arrow Articles by Piesman, J.
Antimicrobial Agents and Chemotherapy, July 2004, p. 2697-2699, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2697-2699.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Sustained-Release Formulation of Doxycycline Hyclate for Prophylaxis of Tick Bite Infection in a Murine Model of Lyme Borreliosis

N. S. Zeidner,1* K. S. Brandt,1 E. Dadey,2 M. C. Dolan,1 C. Happ,1 and J. Piesman1

Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80522,1 Atrix Laboratories, Fort Collins, Colorado 805252

Received 18 December 2003/ Returned for modification 31 December 2003/ Accepted 5 March 2004

The prophylactic potential of a single injection of sustained-release doxycycline hyclate (Atridox) was compared to that of a single oral dose of doxycycline hyclate in a murine model of Lyme borreliosis. Prophylaxis, as measured by the lack of cultivable spirochetes and demonstrable pathology, was noted for 43% of orally treated mice; in contrast, the sustained-release doxycycline hyclate completely protected mice from infection and resultant pathology.

* Corresponding author. Mailing address: Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, P.O. Box 2087, Rampart Rd., Foothill Campus, Fort Collins, CO 80522. Phone: (970) 221-6495. Fax: (970) 221-6476. E-mail: naz2{at}cdc.gov.

Antimicrobial Agents and Chemotherapy, July 2004, p. 2697-2699, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2697-2699.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.